Automated DNA Extraction System

描述(申请人提供)：从根本上说，癌症是一种遗传性疾病。生殖系变异和体细胞突变不仅影响癌症风险，而且还影响这种疾病的治疗、进展和生存。因此，为了了解癌症的遗传影响，在高通量技术的支持下进行大规模的基因组研究是必要的。基因组数据打开了“黑匣子”，并提供了有关易患癌症的分子遗传因素、导致个体肿瘤的特定突变、肿瘤的生理学以及患者的生理学的信息。今天，对生殖系遗传学和肿瘤特征的更全面的评估对于发现个性化药物和个性化治疗的生物标记物是至关重要的。这项共享仪器赠款申请的目的是为购买高通量DNA提取系统提供资金。所要求的DNA提取平台是由两家在生物检疫自动化处理方面久负盛名的供应商--启根和泰康--提供的集成解决方案。具体地说，Qiagen AutoPure LS系统提供档案质量、DNA库和基于群体的遗传关联研究所需的高分子量DNA的自动提纯。Qiagen AutoPure系统将与Tecan EVO 150液体处理平台集成，该平台将能够在2D条形码低温管中评估DNA产量、质量、归一化和等量到所需体积。本申请中描述的各种项目的具体目标各不相同，但它们都对高通量系统的共同需求是相同的，该系统可以产生高质量的DNA来支持包括全基因组关联研究(Gwas)、研究环境因素对成人胶质瘤发病的大型案例系列、前列腺癌生物标记物的发现、基因分型和直接测序以研究男性HPV感染的自然历史的努力。该仪器的预计使用情况表明，它将很好地用于所述项目，利用74%的能力。剩余的能力将用于支持其他癌症中心调查人员和倡议，如全面癌症护理机构一般银行协议。该仪器将在组织核心共享资源设施内安装和运行。癌症中心将通过每年购买超过54,000美元的服务合同，为这一仪器提供重要的机构支持，以促进这两个系统的护理和维护。这项提案中描述的主要用户是NIH超过2400万美元资金的主要调查人员。

DESCRIPTION (provided by applicant): Fundamentally cancer is a genetic disease. Germline variations and somatic mutations influence not only cancer risk but also impact the treatment, progression, and survival of this disease. Thus, to understand the genetic influence of cancer, large-scale genomic based research supported by high-throughput technologies is a necessity. Genomic data opens the "black box" and provides information about the molecular genetic factors that predispose individuals to cancer development, the specific mutations that gave rise to an individual tumor, the physiology of a tumor, and the physiology of the patient. Today a more comprehensive evaluation of germline genetics and tumors profiles is essential for the discovery of biomarkers for individualized medicine and personalized therapy. The purpose of this Shared Instrumentation Grant application is to fund the purchase of a high-throughput DNA extraction system. The requested DNA extraction platform is an integrated solution from two well established vendors in biospecimen automated processing, Qiagen and Tecan. Specifically, the Qiagen AutoPure LS system provides automated purification of archival quality, high molecular weight DNA that is required for DNA banking and population-based genetic association studies. The Qiagen AutoPure system will be integrated with a Tecan EVO 150 liquid handling platform that will enable the assessment of DNA yield, quality, normalization and aliquoting into desired volumes in 2D bar-coded cryogenic tubes. The specific aims for various projects described in this application vary, however they all share the common need for a high-throughput system that can generate high quality DNA to support efforts including genome-wide association studies (GWAS), large case series for studying environmental factors on the onset of adult glioma, prostate cancer biomarker discovery, genotyping and direct sequencing to study the natural history of HPV infection in men. Projected usage of this instrument indicates that it will be well used with the described projects utilizing 74% of capacity. Remaining capacity will be utilized to support other Cancer Center investigators and initiatives such as the Total Cancer Care institutional general banking protocol. The instrument will be housed and operated within the Tissue Core Shared Resource facility. The Cancer Center will provide significant institutional support for this instrumentation by purchasing over $54,000 in yearly service contracts to facilitate the care and maintenance of the both system. Major users described in this proposal are principal investigators on over $24-million dollars in NIH funding.